checkAd

     450  0 Kommentare Apollo Endosurgery Announces DDW 2019 Clinical Highlights

    Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced highlights from DDW 2019 which took place from May 18th to May 21st in San Diego.

    During the 3-day conference, there were over 40 clinical presentations that described results from the use of Apollo’s products in various clinical situations of which over 30 related to procedures that used the OverStitch endoscopic suturing system. Some of the noteworthy abstracts concerning OverStitch that were presented at DDW are highlighted below.

    Endoscopic Sleeve Gastroplasty (ESG)

    Long-Term Follow up and Outcomes After ESG for Treatment of Obesity (5 Year Data). Authors: Kaveh Hajifathalian, Bryan Ang, Qais Maher Dawod, Shawn Laxmikant Shah, Enad Dawod, Amit Mehta, Saurabh Mukewar, SriHari Mahadev, Kartik Sampath, David L. Carr-Locke, Danny Issa, Louis J. Aronne, Rekha Kumar, Alpana Shukla, Reem Z. Sharaiha. Cornell, NYC, New York, United States.

    This abstract included the first 5-year patient data on the ESG procedure. Of those patients who had reached the 5 year follow-up mark, 69% of patients remained at least 10% below their initial total body weight with an average total body weight loss (“TBWL”) of 14.5%.

    Endoscopic Sleeve Gastroplasty: A Meta-Analysis of Weight Loss Outcomes. Authors: Edward Villa, Christopher Grant Chapman. Center for Endoscopic Research and Therapeutics, University of Chicago, Chicago, Illinois, United States.

    This meta-analysis evaluated the effectiveness of ESG in terms of TBWL, excess body weight loss (“EBWL”), and body mass index (“BMI”). Five studies with 550 patients showed pooled 6-month TBWL of 15.6% and five studies with 365 patients were used for pooled 12-month TBWL of 17.0%. For EBWL, six studies with 337 patients were used for pooled 6-month EBWL of 56.3% and four studies with 223 patients were used for pooled 12-month EBWL of 67.8%. Finally, five studies with 301 patients were used to derive pooled 6-month BMI decrease of 13.1% and five studies with 332 patients for pooled 12-month BMI decrease of 14.5%.

    Evaluation of Weight Loss and Adverse Events Associated with ESG: A Pooled Analysis with Systematic Review. Authors: Zohair Ahmed1, Najib Nassani1, Jean M. Chalhoub2, Brian R. Boulay.1 1Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, Illinois, United States; 2Gastroenterology and Hepatology, University of Massachusetts Medical Center, Springfield, Massachusetts, United States.

    Seite 1 von 4



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Apollo Endosurgery Announces DDW 2019 Clinical Highlights Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced highlights from DDW 2019 which took place from May 18th to May 21st in …